New hope for Hard-to-Treat cancers? early trial launches

NCT ID NCT06265688

Recruiting now Disease control Sponsor: CytomX Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This first-in-human study tests an experimental drug called CX-2051, alone or with Avastin, in 160 adults with advanced solid tumors that have worsened after standard treatment. The main goals are to check safety and find the right dose, while also looking for early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CX-2051 (investigational drug) and bevacizumab (Avastin)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early (Phase 1) trial, so the drug may not be safe or effective. Side effects are unknown, and only a small number of participants will receive the optimal dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Carolina BioOncology Institute, PLLC
RECRUITING

Huntersville, North Carolina, 28078, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Montefiore Medical Center
RECRUITING

The Bronx, New York, 10461, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
START - Dallas/Fort Worth
RECRUITING

Fort Worth, Texas, 76104, United States
START San Antonio LLC
RECRUITING

San Antonio, Texas, 78229, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute, LLC
RECRUITING

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.